Tracy Staton

Biography for Tracy Staton

Tracy Staton is the editor of FiercePharma. She has been a freelance writer for five years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at or find her on LinkedIn.

Articles by Tracy Staton

Roche breast cancer drugs Perjeta, Kadcyla are built for speed, report finds

Roche's new set of HER2-positive breast cancer drugs are making it big with oncologists.

Add 3 more biotechs to the IPO list: Agile, Aldeyra and GlobeImmune

Three more biotechs are aiming for IPOs amid a frenzy of public offerings in the industry. Agile Therapeutics, Aldeyra Therapeutics and GlobeImmune are hoping to raise a combined $132 million.

New incontinence data could give Ipsen's Dysport a path to lucrative urology use

Ipsen announced "positive results" in a Phase II trial of Dysport in patients with urinary incontinence. That could put Ipsen's drug in line for more head-to-head competition with Allergan's Botox, which has successfully expanded into several medical uses.

Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales

ThromboGenics admitted last month that slow U.S. sales of its lead drug had put it into a quandary. What could it do to turn the tide? Explore strategic options. Now, the company says sales lagged further for the second half of 2013.

Novo Nordisk taps bankers for potential IT unit spinoff

Novo Nordisk has stepped closer to a spinoff. The Danish drugmaker wants to hive off its information technology business, NNIT, and it has chosen Morgan Stanley and Danske Bank to advise it on the potential deal.

Intercept's lead drug boasts success in PhIII after worrisome side-effects disclosure

Intercept Pharmaceuticals delivered a bad news-good news punch over the weekend about its lead drug.

Italian prosecutors home in on Roche, Novartis execs in eye-drug collusion probe

Itlaian prosecutors have zeroed in on four executives at Roche and Novartis in their probe of potential fraud in the companies' eye-drug sales, Reuters reports, citing sources. The four executives weren't identified.

In latest marketing-reform move, GSK recruits in-house doctors to speak for products

GlaxoSmithKline may be phasing out speaking fees for doctors, but that doesn't mean doctors won't be speaking about its products. As Bloomberg reports, the company plans to add physicians to its in-house marketing staff.

Tokyo hospital exec says Novartis employees deeply involved in leukemia-drug trial

Novartis employees were more involved in a Japanese drug study than previously suspected. The University of Tokyo Hospital said doctors not only let Novartis employees collect patient data from various trial sites but also allowed the Swiss drugmaker into its records on all 255 trial participants.

Analysts see $1.5B boost for Pfizer on 'better than expected' Prevnar 13 data

Pfizer's Prevnar 13 vaccine slashed the number of pneumonia cases in older adults, according to details from a new study that could add up to $1 billion to its global sales.